Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study
Journal
Therapeutic advances in medical oncology
Journal Volume
15
Date Issued
2023
Author(s)
Dai, Ming-Shen
Chao, Ta-Chung
Chiu, Chang-Fang
Shiah, Her-Shyong
Jackson, Christopher G C A
Hung, Noelyn
Zhi, Jianguo
Cutler, David L
Kwan, Rudolf
Kramer, Douglas
Chan, Wing-Kai
Qin, Albert
Tseng, Kuan-Chiao
Hung, Cheung Tak
Chao, Tsu-Yi
Abstract
Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous form. Encequidar (E) is a first-in-class, minimally absorbed, gut-specific oral P-gp inhibitor that facilitates the oral absorption of paclitaxel.
Subjects
HM30181A; P-gp inhibitor; efficacy; encequidar; oral paclitaxel; pharmacokinetics; safety
SDGs
Type
journal article